Editorial Board About Us

Neurogenic bladder

All articles from this key word are listed below.

Volume 23, Number 3 Pediatric Urology

Recent Advances in Managing Pediatric Neurogenic Bladder due to Spina Bifida

Rachel Vancavage Alexandra Rehfuss

Spina bifida is the most prevalent permanently disabling birth defect in the world. It results in damage to nerve endings that negatively affect bladder function and can potentially lead to kidney failure. Management of spina bifida continues to evolve, however, improving outcomes for patients with this condition.

Neurogenic bladder Urinary bladder Spinal dysraphism Myelomeningocele

Volume 4, Supplement 4 Supplement

New Frontiers in the Treatment of Overactive Bladder and Incontinence

Michael B Chancellor

Neurogenic bladder Incontinence Duloxetine Pharmacology

Volume 8, Number 3 Meeting Reviews

Best of the 2006 AUA Annual Meeting

Meeting Review

Danil V Makarov Shachi Tyagi Li-Ming Su Michael E Aldridge Tobias Klatte John P Mulhall John P Stein Arie S Belldegrun Michael K Brawer Claus G Roehrborn Jacob Rajfer J Curtis Nickel Victor W Nitti Michael B Chancellor Alan W Partin Ellen Shapiro

Highlights from the 2006 Annual Meeting of the American Urological Association May 20–25, 2006 Atlanta, GA

Prostate cancer Infertility Benign prostatic hyperplasia Bladder cancer Kidney cancer Lower urinary tract symptoms Bladder exstrophy Overactive bladder Interstitial cystitis Stress urinary incontinence Peyronie’s disease Spina bifida Neurogenic bladder Erectile dysfunction Chronic pelvic pain syndrome Chronic prostatitis Tumor markers Androgen replacement therapy Ejaculatory dysfunction Anorectal malformations Renal stones Robotic-assisted radical prostatectomy

Volume 10, Number 3 Review Articles

Overactive Bladder: Pharmacologic Treatments in the Neurogenic Population

Treatment Update

William B DeVoe Michael J Kennelly

Patients with neurologic disease commonly develop overactive bladder (OAB) symptoms of urgency, frequency, and/or urge incontinence. Although treatment for idiopathic OAB has been extensively studied, therapy for those individuals with neurogenic-mediated OAB has not been thoroughly evaluated. Included in the present article is a description of micturition neurophysiology and a neurourologic evaluation scheme. The pharmacologic treatment options for neurogenic OAB, mainly antimuscarinics and chemical denervation, are reviewed and important studies are discussed. Management of OAB in the neurogenic population is a complex issue with no uniform treatment strategy, and individualized treatment with first-line pharmacologic therapy is often recommended. [Rev Urol. 2008;10(3):182-191]

Overactive bladder Neurogenic bladder Detrusor overactivity

Volume 19, Number 1 Review Articles

Urinary Tract Stone Development in Patients With Myelodysplasia Subjected to Augmentation Cystoplasty

Management Update

Erika B Bunt Betsy D Hopson Guaqiao Wang Courtney L Shephard Dean G Assimos

Patients with myelodysplasia who have undergone augmentation cystoplasty are at risk for urinary tract stones. We sought to determine the incidence and risk factors for stone development in this population. The charts of 40 patients with myelodysplasia who have undergone augmentation cystoplasty were reviewed. None had a prior history of urinary tract stones. All patients were seen on an annual basis with plain abdominal imaging, renal ultrasonography, and laboratory testing. Statistical analysis included a multivariable bootstrap resampling method and Student’s t-test. Fifteen (37.5%) patients developed stones, 14 with bladder stones and 1 with a solitary renal stone, at a mean of 26.9 months after augmentation. Five (33.3%) developed recurrent bladder stones. The patient with a renal stone never developed a bladder stone. The mean follow-up for the stone formers was 117.2 months and for non–stone formers was 89.9 months. The stone incidence per year was 6.8%. Risk factors included a decline in serum chloride after augmentation (P = .02), female sex, younger age at time of augmentation, longer time period since augmentation, and bowel continence. A significant proportion of patients with myelodysplasia subjected to augmentation cystoplasty develop urinary tract stones, predominantly in the bladder. Dehydration may play a role in development of lower urinary tract stones as the decline in serum chloride suggests contraction alkalosis, which could lead to constipation and improved bowel continence. Therefore, improved hydration should be a goal in this cohort. [Rev Urol. 2017;19(1):11-15 doi: 10.3909/riu0741] © 2017 MedReviews®, LLC

Nephrolithiasis Spina bifida Neurogenic bladder augmentation cystoplasty